Avadel Pharmaceuticals 株価情報 (NASDAQ: AVDL)

最新ニュース Avadel Pharmaceuticals (NASDAQ:AVDL) 株価情報

Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals PLC

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) to report quarterly earnings at $3.11 per share on revenue of $7.70 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Deere shares fell 0.1% to $476 in after-hours trading.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year's quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate. Fastly shares dipped 21.5% to $7.91 in the after-hours trading session.</li>
<li>Analysts are expecting GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) to post quarterly earnings at $1.26 per share on revenue of $5.33 billion. The company will release earnings before the markets open. GE HealthCare shares fell 0.1% to $85.82 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) reported stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue of between $697 million and $699 million, versus the $705.71 million estimate, and EPS of between $1.74 and $1.76, versus the $2.00 estimate. HubSpot shares gained 5% to $825.00 in the after-hours trading session.</li>
<li>Analysts expect Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) to post quarterly earnings at $1.81 per share on revenue of $1.83 billion after the closing bell. Coinbase shares gained 3% to $283.10 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43656665/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-telecom-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech &amp; Telecom Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COIN

FSLY

GEHC

HUBS

Deere, GE HealthCare And 3 Stocks To Watch Heading Into Thursday

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is offering discounts up to $6000 on inventory <a href="https://www.benzinga.com/topic/cybertruck">Cybertrucks</a> in the U.S.
What Happened: The company is offering discounts up to $6000 on foundation series Cybertrucks and $5,100 on non-foundation series Cybertrucks in its inventory.
The offers apply to new 2024 model year vehicles.
In January, the company only offered discounts of <a href="https://www.benzinga.com/tech/25/01/43021093/tesla-offers-discounts-up-to-2000-on-new-inventory-cybertrucks">as much as $2000 on non-foundation series </a>Cybertrucks. 
Why It Matters:&nbsp;The Cybertruck is one of Tesla's more premium offerings. The vehicle starts at $79,990 for the base all-wheel drive variant and at $99,990 for the more premium Cyberbeast variant.
According to data from automotive research firm Kelley Blue Book, the Cybertruck was Tesla's third best-selling vehicle in the U.S. in 2024, after its mass-market offerings Model 3 and Model Y.
The company sold&nbsp;<a href="https://www.benzinga.com/25/01/42967593/cybertruck-sales-rise-in-2024-weighed-down-on-tesla-model-s-deliveries-in-us-shows-data" target="_blank" rel="noreferrer noopener">38,965 units in the 12 months through the end of December</a>, significantly higher than the number of Model S or Model X sold in the country.
Tesla made only the foundation series Cybertrucks for the first few months of deliveries. In October, Tesla started selling the <a href="https://www.benzinga.com/25/01/42891397/non-foundation-series-cheaper-cybertrucks-join-tesla-inventory">regular version of Cybertruck </a>priced about $20,000 lower than the foundation series. The foundation series refers to a limited and pricier edition of the Cybertruck with laser-etched foundation series badges and premium accessories.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43650738/nasa-alters-timelines-to-expedite-return-of-astronauts-sunita-williams-butch-wilmore-stranded-at-iss-for-over-8-months">NASA Alters Timelines To Expedite Return Of Astronauts Sunita Williams, Butch Wilmore Stranded At Space Station For Over 8 Months</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Hikes Discounts On Cybertrucks By 3X To $6000 As It Looks To Clear 2024 Inventory

A suspected gas explosion at the Shin Kong Mitsukoshi shopping mall in Taichung, Taiwan&#8217;s Situn District killed one person and critically injured five others on Wednesday morning, according to local authorities. Emergency responders are continuing rescue efforts and investigating the cause.
The explosion, which occurred on the mall&#8217;s 12th floor at 11:33 a.m. local time, also sent at least 12 people to hospitals, <a href="https://www.taipeitimes.com/News/front/archives/2025/02/13/2003831827">reported</a> Taipei Times.
Reports suggest a possible gas leak while a restaurant was changing a gas canister or ongoing renovations in the food court.
The Taichung Fire Bureau stated that the exact cause remains under investigation.
Police are assisting with evacuations and traffic control as officials warn motorists to avoid the area. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43681236/bitcoin-ethereum-dogecoin-spike-amid-hotter-than-expected-inflation-numbers-eths-decisive-move-above-3000-could-restore-confidence-says-analyst">Bitcoin, Ethereum, Dogecoin Spike Amid Hotter-Than-Expected Inflation Numbers: ETH&#8217;s Decisive Move Above $3,000 Could Restore Confidence, Says Analyst</a></li>
</ul>
Image Via Shutterstock

Global

Taiwan Mall Explosion Kills One, Injures Several — Investigation Underway

Macro Economic Events

Econ #s

Economics

Germany Consumer Price Index (YoY) For January 2.3% Vs. 2.3% Est.; 2.6% Prior

Germany Consumer Price Index (MoM) For January -0.2% Vs. -0.2% Est.; 0.5% Prior

U.K. Trade Balance Non-EU For December -6.10B Vs. -7.19B (Revised) Prior

U.K. Trade Balance For December -17.45B Vs. -18.60B Est.; -18.90B (Revised) Prior

U.K. Monthly Gross Domestic Product 3M/3M Change For December 0.1% Vs. -0.1% (Revised) Prior

U.K. Manufacturing Production (MoM) For December 0.7% Vs. 0.0% Est.; -0.3% Prior

U.K. Industrial Production (MoM) For December 0.5% Vs. 0.2% Est.; -0.5% (Revised) Prior

CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) reported a <a href="https://www.benzinga.com/25/02/43655820/cvs-health-stock-surges-on-better-than-expected-q4-earnings-upbeat-annual-outlook">better-than-expected</a> fourth-quarter earnings result and issued an optimistic guidance for the fiscal year 2025 stemming from the expected recovery in its insurance business — Aetna&#8217;s turnaround.
What Happened: The company provided an initial full-year 2025 guidance for adjusted earnings per share (EPS) in the range of $5.75 to $6 per share, which was over 10% above its 2024 full-year EPS of $5.42.
&#8220;Our initial expectations reflect a meaningful recovery in our Aetna business, particularly in Medicare Advantage, as well as continued growth in Health Services,&#8221; said the executive vice president and CEO, David Joyner during the company&#8217;s earnings call.
The CVS Health Aetna business offers health insurance plans, services, and support to individuals, employers, and communities. Whereas, Aetna Medicare Advantage plans, available through Federal Employees Health Benefits, combine Medicare Parts A and B with extra benefits.
&#8220;Our deliberate approach to our 2025 Medicare Advantage bids, combined with our improved Star ratings will improve margins this year and are part of our ongoing commitment to restore this business to target margins of 3% to 5%,&#8221; added Joyner.
Joyner highlighted his observations and priorities during his first 100 days as CEO. It includes a focus on Aetna turnaround, pharmacy transformation, and leadership team development.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43683299/cisco-systems-lands-700m-ai-gold-rush-amid-increased-appetite-from-tech-giants-build-more-and-we-will-buy-more-customers-tell-ceo">Cisco Systems Lands $700M AI Gold Rush Amid Increased Appetite From Tech Giants: &#8216;Build More And We Will Buy More,&#8217; Customers Tell CEO</a>
Why It Matters: The company <a href="https://www.benzinga.com/25/02/43655820/cvs-health-stock-surges-on-better-than-expected-q4-earnings-upbeat-annual-outlook">beat fourth-quarter</a> sales expectations and came in at $97.71 billion. However, the adjusted EPS fell to $1.19, from $2.12 in the same period a year ago, exceeding estimates of $0.93. The EPS decline reflects pressure on healthcare benefits due to utilization and lower Medicare Advantage star ratings.
CVS also guided $6.5 billion in cash flow from operations for 2025.
Price Action: CVS Health rose by 14.95% on Wednesday and advanced by 0.36% in after-hours. The exchange-traded fund tracking the S&amp;P 500 index, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell by 0.32%.
CVS shares have gained 42.97% on a year-to-date basis, whereas it was down by 17.46% over the last year.
The average price target among 28 <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">analysts tracked by Benzinga</a> is $143 with a ‘Buy' rating. The estimates range from $58 to $143 apiece. Recent ratings from Evercore ISI Group, Truist Securities, and Deutsche Bank suggest a $63.67 target, implying a potential upside of 0.34%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CVS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="385" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13012654/CVS-ANR-1024x385.png" alt="" class="wp-image-780259" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13012654/CVS-ANR-1024x385.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13012654/CVS-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13012654/CVS-ANR-768x288.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13012654/CVS-ANR.png 1065w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43650247/marriotts-digital-penetration-hits-historic-highs-as-bonvoy-app-downloads-soar-adding-31-million-new-members-ceo-says-transformation-enhancing-the-customer-experience" target="_blank" rel="noreferrer noopener">Marriott's Digital Penetration Hits ‘Historic Highs' As Bonvoy App Downloads Soar Adding 31 Million New Members</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Insurance

General

CVS Health Forecasts 10% Earnings Growth For 2025, Citing Aetna's 'Meaningful Recovery'

U.K. Gross Domestic Product (QoQ) Preliminary For Q4 0.1% Vs. -0.1% Est.; 0.0% Prior

U.K. Gross Domestic Product (MoM) For December 0.4% Vs. 0.1% Est.; 0.1% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q4 1.4% Vs. 1.1% Est.; 1.0% (Revised) Prior

U.K. Business Investment (QoQ) Preliminary For Q4 -3.2% Vs. -0.4% Est.; 1.9% Prior

ASE Tech Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASX#NYSE">ASX</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.15 by 14 percent. This is a 3.01 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $5.045 billion which missed the analyst consensus estimate of $5.590 billion by 9.75 percent. This is a 0.30 percent increase over sales of $5.030 billion the same period last year.

Earnings Misses

ASE Tech Holding Co Q4 2024 GAAP EPADS $0.13 Misses $0.15 Estimate, Sales $5.045B Miss $5.590B Estimate

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is set to introduce artificial intelligence (AI) features in China in collaboration with Alibaba Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), a move that could potentially stimulate iPhone sales growth in the region, following a challenging period of declining sales.
What Happened: According to a report by&nbsp;Deepwater Management&#8217;s Gene Munster and Brian Baker, Apple&#8217;s business in China has been experiencing a slump, with an average quarterly decline of 7% over the past six quarters. This downturn is largely due to Chinese consumers&#8217; preference for domestic brands and&nbsp;the absence of AI capabilities&nbsp;on iPhones in the region. In the past three years, China&#8217;s smartphone market leadership has transitioned from iPhone to Xiaomi.
However, the anticipated&nbsp;introduction of Apple Intelligence in&nbsp;China, possibly in the June or September quarter, could strengthen the case for a rebound in iPhone sales. However, Munster feels that the 10% growth expectation for iPhone for next year as cited by The Information could be too aspirational. 
&#8220;In this case, I would expect growth closer to 7-8%. If I'm wrong on FY25 and it comes in closer to 1%, I believe the 10% growth expectation is achievable, in part due to the late fiscal year rollout of Apple Intelligence in China,&#8221; stated Munster. 
If Apple Intelligence is launched as speculated, iPhone growth could accelerate over the upcoming eight quarters, especially as these features are introduced in Europe and China. Munster emphasized that this would be irrespective of whether the iPhone sales declined in FY25 or FY26.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43672114/whats-going-on-with-alibaba-shares-wednesday">What&#8217;s Going On With Alibaba Shares Wednesday?</a>
Why It Matters: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43655603/apple-finds-its-ai-wingman-in-alibaba-can-it-power-an-iphone-comeback-in-china">Apple&#8217;s collaboration with Alibaba </a>could be the secret weapon needed to reclaim lost ground in China. This decision follows the termination of Apple&#8217;s previous AI development partnership with China&#8217;s Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>). The Apple-Alibaba partnership is also critical as Xiaomi and Huawei have been gaining market share with their AI-powered smartphones, while Apple&#8217;s latest iPhones have lacked the AI capabilities that have become a key selling point. 
The success of Apple&#8217;s strategy&nbsp;in China will depend on&nbsp;the effective integration of AI into its devices, navigating rising nationalist sentiment, and adapting its pricing strategy to align with changing consumer behaviors.
Meanwhile,&nbsp;BofA Securities analyst Wamsi Mohan <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43668203/apple-teams-up-with-alibaba-for-ai-analyst-says-edge-device-integration-could-boost-growth">reiterated a Buy rating on Apple </a>with a price target of $265. The analyst is confident of Apple&#8217;s reliable cash flows and strong earnings stability, along with its potential advantages from integrating AI into edge devices.
<ul>
<li>READ MORE:<a href="https://www.benzinga.com/markets/25/02/43616825/deepseeks-success-just-the-start-more-ai-funding-still-very-much-required-says-baidu-ceo-you-just-dont-know-when-and-where-innovations-come-from"> DeepSeek&#8217;s Success Just The Start, More AI Funding &#8216;Still Very Much Required,&#8217; Says Baidu CEO: &#8216;You Just Don&#8217;t Know When And Where Innovations Come From&#8217; (CORRECTED)</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

BABA

BIDU

Apple Intelligence Rollout In China And Europe To Boost iPhone Sales, Says Deepwater's Gene Munster

Dividend Declared NorthWestern Energy Group's Board of Directors has declared a quarterly common stock dividend of $0.66 per share, representing a 1.5% increase over the previous quarter's dividend. The dividend is payable on March 31, 2025, to shareholders of record as of March 14, 2025. Looking ahead, we remain committed to maintaining a dividend payout ratio within our targeted range of 60-70% over the long term.

Dividends

Reported Earlier, NorthWestern Energy Group Increases Quarterly Dividend By 1.5% to $0.66 Per Share, Payable March 31, 2025

NorthWestern (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) reported quarterly earnings of $1.13 per share which met the analyst consensus estimate. This is a 18.12 percent decrease over earnings of $1.38 per share from the same period last year. The company reported quarterly sales of $373.500 which missed the analyst consensus estimate of $383.990 million by 100.00 percent. This is a 100.00 percent decrease over sales of $355.966 million the same period last year.

NorthWestern Q4 2024 Adj. EPS $1.13, Inline, Sales $373.500 Miss $383.990M Estimate

Precision Drilling (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDS#NYSE">PDS</a>) reported quarterly earnings of C$1.06 per share which missed the analyst consensus estimate of C$1.93 by 45.08 percent. This is a 89.19 percent decrease over earnings of C$9.81 per share from the same period last year. The company reported quarterly sales of C$468.171 million which missed the analyst consensus estimate of C$481.580 million by 2.78 percent. This is a 7.64 percent decrease over sales of C$506.871 million the same period last year.

Precision Drilling Q4 2024 GAAP EPS C$1.06 Misses C$1.93 Estimate, Sales C$468.171M Miss C$481.580M Estimate

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), Edgewise ...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)

UBS lowered the firm's price target on Avadel Pharmaceuticals (AVDL) to $14 from $22 and keeps a Buy rating on the shares. Avadel reported prelimin...

Avadel Pharmaceuticals price target lowered to $14 from $22 at UBS

3 Oversold Biotech Names

Cogent and ModivCare gain after insider purchases

Avadel Pharmaceuticals (AVDL) announced that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimburs...

Avadel names Sev Melkonian as VP, patient services, distribution, reimbursement

Avadel Pharmaceuticals gains as holder pushes for sale process

Deutsche Bank analyst David Hoang initiated coverage of Avadel Pharmaceuticals (AVDL) with a Buy rating and $12 price target The shares have declin...

Avadel Pharmaceuticals initiated with a Buy at Deutsche Bank

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

IBM initiated, Southwest upgraded: Wall Street's top analyst calls

Avadel Pharmaceuticals: Moving To A Speculative Buy

AVDL

BIIB

COGT

DOMO

DVAX

EWTX

FLNC

FOLD

FSLR

JAZZ

MODV

PTON

QTTB

RGNX

STLD

TKPHF

VKTX

Legal

Press Releases

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Health Care

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Analyst Ratings

Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Management

Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Deutsche Bank

Piper Sandler

HC Wainwright & Co.

Needham

Comments

Avadel Pharmaceuticals

ニュース

最新ニュース Avadel Pharmaceuticals (NASDAQ:AVDL) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル